1429027-74-6

Basic information

• Product Name: 2-(benzyloxy)-1-bromo-4-(trifluoromethyl)benzene
• Synonyms: 2-(benzyloxy)-1-bromo-4-(trifluoromethyl)benzene
• CAS NO: 1429027-74-6
• Molecular Weight: 331.132
• Mol File: 1429027-74-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-(benzyloxy)-1-bromo-4-(trifluoromethyl)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(benzyloxy)-1-bromo-4-(trifluoromethyl)benzene(1429027-74-6)
• EPA Substance Registry System: 2-(benzyloxy)-1-bromo-4-(trifluoromethyl)benzene(1429027-74-6)

Safety Data

• Hazardous Substances Data: 1429027-74-6(Hazardous Substances Data)

Usage

General Description

2-(benzyloxy)-1-bromo-4-(trifluoromethyl)benzene is an organic compound that contains a benzene ring with a bromine and trifluoromethyl group as well as a benzyloxy group attached to it. This chemical is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals. It is also used as a reagent in organic synthesis and is known for its ability to undergo nucleophilic substitution reactions to form a wide range of derivatives. Additionally, it has potential applications in the field of materials science, specifically in the development of advanced materials with unique properties. Overall, 2-(benzyloxy)-1-bromo-4-(trifluoromethyl)benzene is a versatile compound that has numerous uses in the chemical and pharmaceutical industries.

Upstream product

• 402-07-3 1-bromo-2-methoxy-4-(trifluoromethyl)benzene 
• 100-39-0 benzyl bromide 
• 402-05-1 2-bromo-5-(trifluoromethyl)phenol 

Relevant articles and documents

Identification of Highly Selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors by a Covalent Fragment-Based Approach

Covalent ligands are of great interest as therapeutic drugs or biochemical tools. Here, we reported the discovery of highly selective and irreversible inhibitors of lipoprotein-associated phospholipase A2 (Lp-PLA2) using a covalent fragment-based approach. The crystal structure of Lp-PLA2 in complex with a covalent fragment not only reveals the covalent reaction mechanism but also provides a good starting point to design compound 8, which has a more than 130,000-fold and 3900-fold increase in potency and selectivity, respectively, compared to those of the covalent fragment. Furthermore, fluorescent probes with high selectivity and sensitivity are developed to characterize Lp-PLA2 and its enzymatic activity in vitro or even in living cells in a way more convenient than immunoblotting tests or immunofluorescence imaging. Overall, we provide a paradigm for application of the covalent fragment-based strategy in covalent ligand discovery and the advantage of enol-cyclocarbamate as a new warhead in designing covalent inhibitors of serine hydrolases.

Oxazolidinone compound as well as preparation method, application and pharmaceutical composition thereof

The invention relates to an oxazolidinone compound used as an Lp-PLA2 covalent inhibitor and a pharmaceutical composition of the oxazolidinone compound, the structure of the oxazolidinone compound isshown as a general formula I, and R1, R2 and R3 are defined as the specification and claims. The compound shown in the general formula I or the stereoisomer or the pharmaceutically acceptable salt thereof can be used as the Lp-PLA2 covalent inhibitor to prevent and/or treat and/or improve diseases related to Lp-PLA2 enzyme activity. Meanwhile, the stereoisomer or the pharmaceutically acceptable salt of the compound shown in the general formula I can be used as an Lp-PLA2 specific molecular probe.

DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS

The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.